literature

HIV mutation literature information.

Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.

PMID: 24746180 2014 Journal of the International AIDS Society

Result: Of note, in the analysed sample, in six patients (2.5%) key NNRTI mutations not associated with RPV were noted, with K103N being the most common (five cases, 2.1%), including one case with a triple K101E/K103N/G190A mutation and one with K103N/P225H/K238T.

High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.

PMID: 24816790 2014 PloS one

Result: The most common NNRTI mutation in this group was K103N (n = 152, 57.4%) followed by V106M (n = 105, 39.6%), P225H (n = 42, 15.8%) and V179D (n = 29, 10.9%, Figure 1).

[Resistance evolutionary pathway analysis of HIV-1 CRF_07BC reverse transcriptase].

PMID: 24969455 2014 Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Abstract: While for B subtype, the major resistance mutations include M184V, K103N,Y181C, T69N,G190A, K238T,Y188H and P225H.

Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.

PMID: 25006528 2014 ISRN AIDS

Discussion: L100I, K101P, P225H, F227L, M230L, and K238T are secondary mutations that usually occur in combination with one of the primary NNRTI resistance mutations.

Discussion: Of these secondary mutations P225H (1/19) & K238T/N (2/19) were the secondary NNRTI mutation seen in our study.

Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.

PMID: 25166019 2014 PloS one

Result: The Y181C/I (N = 5, 33.3%), A98S/G (n = 4, 27%), H221Y (n = 2, 13%) and P225H (N = 1, 7.5%) mutations were only seen in pre-treated patients.

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.

PMID: 25926858 2014 AIDS research and therapy

Result: One patient (patient 14 in Table 4) showed the transient development of the N[t]RTI RAM L74I/L and the NNRTI RAM P225H/P at the Week 16 visit, which were not detected at the subsequent Week 48 visit analysis as shown in Table 4.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

PMID: 23079810 2013 AIDS (London, England)

Result: The L100I (36%), K103N (79%), and P225H (21%) mutations were more common in efavirenz based regimens as compared to nevirapine based regimens [Table 3].

HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection.

PMID: 23161095 2013 Journal of medical virology

Abstract: DRAMs to NNRTIs were V106I (7%), V179D (4.2%), V179T (1.8%), E138A (1.5%), V90I (1.2%), K103N (0.9%), Y181C (0.9%), and P225H (0.3%).

Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.

PMID: 23469241 2013 PloS one

Table: P225H

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Result: Additional NNRTI-resistance mutations not shown in Table 4 included (i) A98G, which occurred in 3.3% of NNRTI-treated patients; (ii) V106A, which occurred in 0.6% of NNRTI-treated patients; (iii) E138G/Q, which occurred in 0.9% and 0.9% of patients, respectively; (iv) V179D/E/T/F, which occurred in 8.5%, 0.7%, 0.5%, and 0% of NNRTI-treated patients respectively; (v) Y181I/V, which occurred in one and no patient, respectively; (vi) H221Y, which occurred in 5.9% of EFV-treated and 9.3% of NVP-treated patients (p<0.001); (vii) P225H, which occurred in 13.6% of EFV-treate

Browser Board

Co-occurred Entities

Filtrator